Is There a Generic for Verkazia?

No. The Orange Book lists no active FDA-approved generic (ANDA) for Verkazia (cyclosporine). The Orange Book shows its last listed patent expires June 2, 2029 and its last listed exclusivity ends June 23, 2028.

Run it in Rivvi

Map Verkazia and your other top fills to their generics

Every strength in RxNorm, with brands that have no generic flagged.

Build the map

Free to start. Opens Rivvi, the AI workspace for healthcare teams.

Verkazia products in the Orange Book

Verkazia products and approved generics
Form and route	Strength	Brand status	Brand TE	Active generics	Generic TE codes
emulsion, ophthalmic	0.1%	Marketed (Rx)	None	0	None

NDA 214965, held by HARROW EYE LLC. Active generics are ANDA products in the Orange Book prescription list with the same ingredient, dosage form, route and strength.

Verkazia patents

Patents listed for Verkazia
Patent	Expires	Covers	Use code	NDA
11612658	January 27, 2026	Method of use	U-3560	214965
9220694	January 27, 2026	Drug product	None	214965
9956289	January 27, 2026	Drug product	None	214965
7973081	January 27, 2026	Drug product	None	214965
8524779	January 27, 2026	Drug product	None	214965
8298568	November 3, 2027	Drug product	None	214965
9132071	June 2, 2029	Drug product	None	214965

Verkazia exclusivity

Exclusivity listed for Verkazia
Code	Meaning	Expires	NDA
ODE-358	Orphan drug exclusivity	June 23, 2028	214965

Verkazia NDC codes

Questions

Is there a generic for Verkazia?

No. The Orange Book lists no active FDA-approved generic (ANDA) for Verkazia (cyclosporine). The Orange Book shows its last listed patent expires June 2, 2029 and its last listed exclusivity ends June 23, 2028.

What is the generic name for Verkazia?

The active ingredient in Verkazia is cyclosporine, per the FDA Orange Book.

When does the Verkazia patent expire?

The last patent listed for Verkazia in the Orange Book expires June 2, 2029. A listed patent expiry date is not a generic launch date.

What does a therapeutic equivalence code mean?

In the Orange Book, codes that start with A (such as AB) mean FDA considers the product therapeutically equivalent to the reference drug. Codes that start with B mean FDA does not, at this time, consider the product therapeutically equivalent.